Table 1. Tumour characteristics in the TP53-negative and TP53-positive group.
| TP53(−) N=94 | TP53(+) N=135 | P-valuea | |
|---|---|---|---|
| Age | |||
| Range | 24–76 | 25–77 | 0.57 |
| mean (s.d.) | 52.4 (11.1) | 53.7 (9.9) | |
| FIGO stage | |||
| IIB | 4 (4%) | 6 (4%) | |
| IIC | 2 (2%) | 5 (4%) | |
| IIIA | 4 (4%) | 4 (3%) | 0.8 |
| IIIB | 19 (20%) | 26 (19%) | |
| IIIC | 51 (54%) | 78 (58%) | |
| IV | 14 (15%) | 16 (12%) | |
| Residual tumour | |||
| 0–2 cm | 44 (47%) | 65 (48%) | 0.92 |
| >2 cm | 50 (53%) | 70 (52%) | |
| Histological type | |||
| Serous | 63 (67%) | 114 (84%) | |
| Endometrioid | 9 (10%) | 5 (4%) | 0.001 |
| Clear cell | 12 (13%) | 0 | |
| Undifferentiated | 5 (5%) | 8 (7%) | |
| Other | 5 (5%) | 7 (5%) | |
| Histological grade | |||
| G2 | 19 (20%) | 11 (8%) | |
| G3 | 55 (59%) | 87 (64%) | 0.032 |
| G4 | 20 (21%) | 37 (27%) | |
| Chemotherapy | |||
| CP | 70 (75%) | 95 (70%) | |
| CAP | 24 (25%) | 40 (30%) | |
| Response to chemotherapy | |||
| Complete remission | 46 (49%) | 74 (55%) | |
| Partial remission | 11 (12%) | 24 (18%) | |
| No change | 4 (4%) | 4 (3%) | |
| Progression | 33 (35%) | 33 (24%) | |
| Platinum resistant | 53 (56%) | 77 (57%) | |
| Platinum sensitive | 41 (44%) | 58 (43%) | |
| Recurrence rate in a CR group | 34/46 (74%) | 58/74 (78%) | |
| Outcome | |||
| NED | 12 (13%) | 23 (17%) | |
| AWD | 9 (10%) | 17 (13%) | |
| DOD | 70 (75%) | 94 (70%) | |
| DOC | 3 (3%) | 1 (1%) |
CP=cyclophosphamide and cisplatin, CAP=CP plus doxorubicin, CR=complete remission, NED=no evidence of disease, AWD=alive with disease, DOD=died of disease, DOC=died of other causes
a
χ2 test.